Timing of Telmisartan (40 mg) for Treating High Blood Pressure in Diabetic Patients: A Study of Blood Pressure Changes During Exercise and Monitoring Through the Day

Chronotherapy of hypertension with telmisartan 40 mg in diabetic hypertensive patients using ambulatory blood pressure monitoring and evaluation of blood pressure response during treadmill exercise: a cross-over randomized controlled trial. - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/092351

Enrollment

Registered

2025-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E115- Type 2 diabetes mellitus with circulatory complications

Interventions

Intervention1: Daytime dosing of telmimsartan 40mg: Based upon inclusion and exclusion criteria, patient will be started on Tablet telmisartan 40mg per oral in the morning for 8 weeks Control Interve

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults aged over 18 years 2. Diagnosed with both diabetes and hypertension

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Morning Versus Bedtime Dosing Of Antihypertensive In Diabetic Hypertensive PatientsTimepoint: 4 months 10 days	—

Secondary

Measure	Time frame
to identify nocturnal dipping patternTimepoint: 4 months 10 days	—

Countries

India

Contacts

Public ContactNalabothula Raviteja

srm medical collage and research centre

nandakur@srmist.edu.in8667741559

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026